AU2010273642B2 - GPR119 agonists - Google Patents

GPR119 agonists Download PDF

Info

Publication number
AU2010273642B2
AU2010273642B2 AU2010273642A AU2010273642A AU2010273642B2 AU 2010273642 B2 AU2010273642 B2 AU 2010273642B2 AU 2010273642 A AU2010273642 A AU 2010273642A AU 2010273642 A AU2010273642 A AU 2010273642A AU 2010273642 B2 AU2010273642 B2 AU 2010273642B2
Authority
AU
Australia
Prior art keywords
mmol
methanesulfonyl
pharmaceutically acceptable
tetrahydro
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010273642A
Other languages
English (en)
Other versions
AU2010273642A1 (en
Inventor
David Gene Barrett
Ana Belen Bueno Melendo
Jeffry Bernard Franciskovich
Bin Liu
Kumiko Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010273642(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2010273642A1 publication Critical patent/AU2010273642A1/en
Application granted granted Critical
Publication of AU2010273642B2 publication Critical patent/AU2010273642B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU2010273642A 2009-07-15 2010-07-12 GPR119 agonists Ceased AU2010273642B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382114.8 2009-07-15
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
US61/245,445 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (2)

Publication Number Publication Date
AU2010273642A1 AU2010273642A1 (en) 2012-01-19
AU2010273642B2 true AU2010273642B2 (en) 2014-03-13

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010273642A Ceased AU2010273642B2 (en) 2009-07-15 2010-07-12 GPR119 agonists

Country Status (24)

Country Link
US (1) US8207344B2 (US07794700-20100914-C00152.png)
EP (1) EP2454251A1 (US07794700-20100914-C00152.png)
JP (1) JP5715127B2 (US07794700-20100914-C00152.png)
KR (1) KR101365854B1 (US07794700-20100914-C00152.png)
CN (1) CN102471313B (US07794700-20100914-C00152.png)
AR (1) AR077638A1 (US07794700-20100914-C00152.png)
AU (1) AU2010273642B2 (US07794700-20100914-C00152.png)
BR (1) BRPI1015921A2 (US07794700-20100914-C00152.png)
CA (1) CA2764906C (US07794700-20100914-C00152.png)
CO (1) CO6480977A2 (US07794700-20100914-C00152.png)
CR (1) CR20120012A (US07794700-20100914-C00152.png)
DO (1) DOP2012000006A (US07794700-20100914-C00152.png)
EA (1) EA020540B1 (US07794700-20100914-C00152.png)
EC (1) ECSP12011606A (US07794700-20100914-C00152.png)
IL (1) IL216776A0 (US07794700-20100914-C00152.png)
MA (1) MA33428B1 (US07794700-20100914-C00152.png)
MX (1) MX2012000704A (US07794700-20100914-C00152.png)
NZ (1) NZ597125A (US07794700-20100914-C00152.png)
PE (1) PE20121045A1 (US07794700-20100914-C00152.png)
SG (1) SG177646A1 (US07794700-20100914-C00152.png)
TN (1) TN2012000002A1 (US07794700-20100914-C00152.png)
TW (1) TWI429634B (US07794700-20100914-C00152.png)
WO (1) WO2011008663A1 (US07794700-20100914-C00152.png)
ZA (1) ZA201200227B (US07794700-20100914-C00152.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374766T1 (de) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) * 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2831334A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2012173917A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062838A1 (en) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
RU2603346C2 (ru) * 2012-06-12 2016-11-27 Чхон Кхун Дан Фармасьютикал Корп. Производные пиперидина в качестве агонистов gpr119
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
PT3074384T (pt) * 2013-11-26 2019-07-10 Chong Kun Dang Pharmaceutical Corp Derivados de amida para o agonista gpr119
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope Inc AMPK ACTIVATORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374766T1 (de) * 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP2059517A1 (en) * 2006-08-30 2009-05-20 Biovitrum AB (publ) Pyrimidine compounds for treating gpr119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Also Published As

Publication number Publication date
TWI429634B (zh) 2014-03-11
ZA201200227B (en) 2013-06-26
ECSP12011606A (es) 2012-02-29
MX2012000704A (es) 2012-03-07
IL216776A0 (en) 2012-03-01
NZ597125A (en) 2013-08-30
EA201270169A1 (ru) 2012-06-29
PE20121045A1 (es) 2012-08-09
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
SG177646A1 (en) 2012-02-28
CN102471313B (zh) 2014-06-04
MA33428B1 (fr) 2012-07-03
US8207344B2 (en) 2012-06-26
KR101365854B1 (ko) 2014-02-21
TN2012000002A1 (en) 2013-09-19
EA020540B1 (ru) 2014-11-28
DOP2012000006A (es) 2012-01-31
JP5715127B2 (ja) 2015-05-07
AR077638A1 (es) 2011-09-14
TW201114757A (en) 2011-05-01
AU2010273642A1 (en) 2012-01-19
EP2454251A1 (en) 2012-05-23
CA2764906A1 (en) 2011-01-20
WO2011008663A1 (en) 2011-01-20
US20110015199A1 (en) 2011-01-20
JP2012533546A (ja) 2012-12-27
CA2764906C (en) 2014-06-10
CR20120012A (es) 2012-03-28
KR20120024964A (ko) 2012-03-14
CO6480977A2 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
AU2010273642B2 (en) GPR119 agonists
EP4059929A1 (en) Glp-1 receptor agonist and use thereof
DE602006000339T2 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
WO2008025800A1 (en) Pyrimidine compounds for treating gpr119 related disorders
US10023593B2 (en) ALK kinase inhibitor, and preparation method and uses thereof
EA018709B1 (ru) Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
JP2023508914A (ja) プロテインチロシンホスファターゼ分解剤及びその使用方法
TW201835072A (zh) 新穎cyp11a1抑制劑
CA2811525A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
JP2013530947A (ja) Gpr119調節薬としてのピペリジニル置換ラクタム
TW200526625A (en) Pharmaceutically active compounds
TW201209054A (en) Novel compounds
WO2012138845A1 (en) Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
TW202136271A (zh) 呋喃并吲唑衍生物
TW202128658A (zh) Glp-1受體促效劑及其用途
EP2771000B1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
TW201039827A (en) Indoline compound
WO2013062835A1 (en) Substituted piperidinyl compounds useful as gpr119 agonists
KR101372743B1 (ko) Nk3 수용체 길항제로서 피페리딘 유도체
TW201938533A (zh) 經脲及苯基取代之哌啶或哌啶酮
KR20150060573A (ko) Gpr119 활성의 조절제로서의 아마이드 유도체
US20240308980A1 (en) Heteroaryl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2015167309A1 (ko) 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
NZ715471A (en) Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119
NZ715471B2 (en) Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired